武警医学2026，Vol.37Issue(3)：230-234,5.
替奈普酶静脉溶栓联合丁苯酞注射液治疗急性脑梗死的临床疗效
Clinical efficacy of tenecteplase intravenous thrombolysis combined with butylphthalide injection in the treatment of acute cerebral infarction
摘要
Abstract
Objective To explore the clinical efficacy of tenecteplase(TNK)intravenous thrombolysis combined with bu-tylphthalide injection in the patients with acute cerebral infarction(ACI).Methods A total of 60 patients with ACI admitted to Char-acteristics Medical Center of Chinese People's Armed Police Force from January 2024 to March 2025 were selected and randomly di-vided into a control group and a combined treatment group,with 30 patients in each group.Both groups were given the same basic treatment,and the control group was treated with TNK intravenous thrombolysis,while the combined treatment group was treated with TNK intravenous thrombolysis combined with butylphthalide injection.The modified Rankin scale(mRS)scores,serum inflammatory factor levels and adverse reactions were compared before and after treatment between the two groups,and the National Institutes of Health stroke scale(NIHSS)was used to assess the scores of the patients at admission,24 h,7 d,and 90 d after thrombolysis.Results There were no significant differences between the combined treatment group and the control group in mRS score and the levels of serum inflammatory factors at admission(P>0.05).The mRS score of the combined treatment group after treatment(1.30±0.47 points)was lower than that of the control group(2.40±0.50 points),with a statistically significant difference(P<0.05).The levels of serum inflammatory factors IL-6,IL-8,and IL-10 in the combined treatment group were(20.13±3.47)ng/L,(19.33±3.56)ng/L,and(8.34±0.38)ng/L,respectively,which were lower than(24.32±3.61)ng/L,(22.48±3.83)ng/L,and(9.29±0.64)ng/L,respectively in the control group,with a statistically significant difference(P<0.05);There were no significant differences between the combined treatment group and the control group in NIHSS scores at admission and 24 h after thrombolys-is(P>0.05),but the NIHSS score of patients in the combined treatment group was(11.63±1.56)points 7 d after thrombolysis,which was lower than(13.13±1.63)points of the control group,with a statistically significant difference(P<0.05).The NIHSS score of patients in the combined treatment group was(8.47±1.07)points 90 d after thrombolysis,which was lower than(9.57±1.22)points of the control group,with a statistically significant difference(P<0.05).The incidence of adverse reactions in the com-bined treatment group compared to the control group showed no significant difference(P>0.05).Conclusions TNK intravenous thrombolysis combined with butylphthalide injection can improve the recovery of neurological dysfunction and reduce the levels of serum inflammatory factors of patients with ACI,without obvious adverse reactions,which is a safe and effective treatment method.关键词
替奈普酶/丁苯酞/急性脑梗死/静脉溶栓/临床疗效Key words
tenecteplase/butylphthalide/acute cerebral infarction/intravenous thrombolysis/clinical efficacy分类
医药卫生引用本文复制引用
杨细平,石罡,王慧敏,马良,刘紫薇,李建军..替奈普酶静脉溶栓联合丁苯酞注射液治疗急性脑梗死的临床疗效[J].武警医学,2026,37(3):230-234,5.基金项目
天津市医学重点学科建设资助(TJYXZDXK-3-001D) （TJYXZDXK-3-001D）
